|Bid||0.00 x 800|
|Ask||0.00 x 800|
|Day's Range||118.52 - 119.68|
|52 Week Range||95.23 - 130.29|
|PE Ratio (TTM)||89.30|
|Earnings Date||Jul 24, 2018 - Jul 30, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||116.14|
PALO ALTO, Calif. , May 23, 2018 /PRNewswire/ -- Varian (NYSE: VAR) today announced that Gary Bischoping , chief financial officer, and J. Michael Bruff , senior vice president of investor relations, will ...
Stock Research Monitor: EYES, SENS, and VAR LONDON, UK / ACCESSWIRE / May 23, 2018 / If you want a free Stock Review on PBH sign up now at www.wallstequities.com/registration . Ahead of today's trading ...
Varian Medical Systems said it would not increase its offer to buy Australian liver cancer treatment provider Sirtex Medical Ltd after Sirtex on Tuesday said Chinese private equity firm CDH Investments had submitted a formal bid. CDH Investments this month made a last-minute offer of $1.4 billion, or A$33.60 per share, for Sirtex Medical, topping Varian Medical Systems' proposal days before the U.S. firm was set to seal a takeover deal.
Sirtex has notified Varian of the material terms and conditions of the CDH Proposal, and also announced them to the Australian Securities Exchange. Under the terms of the scheme of arrangement entered into between Sirtex and Varian (Varian Scheme), Varian has the right to submit a counterproposal to the CDH Proposal. Varian has formally notified Sirtex that it will not be submitting a counterproposal and that Varian is committed to the terms of the Varian Scheme at the purchase price offered by Varian of A$28 per share. The board of directors of Sirtex is considering the relative merits and risks of the CDH Proposal compared to the Varian Scheme, including the respective offer prices, the risks and timing to completion and the potential outcomes for Sirtex shareholders if a control transaction does not complete. The board of directors of Sirtex has not yet formed a view on these matters and continues to unanimously support and recommend the Varian Scheme.
Australian liver cancer treatment provider Sirtex Medical Ltd on Tuesday said it received a binding takeover offer from Chinese private equity firm CDH Investments. CDH Investments this month made a last-minute offer of $1.4 billion, or A$33.60 per share, for Sirtex Medical, topping Varian Medical Systems days before the U.S. firm was set to seal a takeover deal.
Varian Medical (VAR) opts to spread radiotherapy accessibility in Latin America through Brazil MOH, other international ventures of the company hold promise.
Successive product launches and a marked progress in precision medicine initiatives boost Thermo Fisher's (TMO) performance.
Post takeover of Abaxis' (ABAX) point-of-care diagnostic instruments, Zoetis expects the consolidated company's veterinary diagnostics category to speed up growth over the animal health industry.
Veeva Systems' (VEEV) new commercial data warehouse establishes a solid data foundation, which will boost AI and analytics in the MedTech industry.
BRASÍLIA, Brazil and PALO ALTO, Calif. , May 17, 2018 /PRNewswire/ -- Varian (NYSE: VAR) today announced it has signed a software technology training and education cooperation agreement with the Brazil ...
PALO ALTO, Calif. , May 16, 2018 /PRNewswire/ -- Varian (NYSE: VAR) announced two patients with brain cancer were the first patients in Korea to be treated using the company's HyperArc ™ High Definition ...
Glancy Prongay & Murray LLP continues its investigation on behalf of Varian Medical Systems, Inc. investors concerning the Company and its directors’ and officers’ possible violations of state laws.
NEW YORK, May 15, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Liberty ...
Additionally, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on February 2. Index (PMI) data, output in the Healthcare sector is rising.
Strong performance in Europe and Rest of World boosts DENTAPLY's (XRAY) performance in Q1. However, a lowered guidance indicates looming concerns.
PALO ALTO, Calif. and TAIPEI, Taiwan , May 7, 2018 /PRNewswire/ -- Varian (NYSE:VAR) today announced it has acquired Cooperative CL Enterprises (COOP), a leading distributor of radiotherapy equipment ...